Business Card for Jim Ferenz:


Director of Facilities
 Seal Beach , CA area
Email Avail: 3 Day Free Trial


1700 Saturn Way
Seal Beach , CA 90740
Tel: (877) 256-4545

Last updated on 2017-12-18

About Jim Ferenz:

Jim Ferenz works as an Director of Facilities for Dendreon at Seal Beach , CA. The company's webpage is http://www.dendreon.com. For email, phone number and executive profiles for Director of Facilities and other executives of Dendreon at Seal Beach , CA, check Dendreon at Joesdata.com. Not the Jim Ferenz you are looking for? Do a quick search in our website and find other people named Jim Ferenz.
Jim Ferenz's Work History:
No information available..

Jim Ferenz's Education:
No information available..

Jim Ferenz's Co-workers:
As of August 13, 2022, Jim Ferenz has 169 co-workers under the company name Dendreon at Joesdata.com.

About Dendreon:

Dendreon Corporation (Dendreon) is a biotechnology company focused on the discovery, development and commercialization of therapeutics that may improve cancer treatment options for patients. Dendreon?s product portfolio includes active cellular immunotherapy and small molecule product candidates to treat a range of cancers. PROVENGE (sipuleucel-T), is a autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic, metastatic, castrate-resistant (hormone-refractory) prostate cancer. The Company owns worldwide rights for PROVENGE. Other product candidates it has under development include investigational cellular immunotherapies targeted towards HER2/neu for the treatment of patients with bladder, breast, ovarian and other solid tumors, carbonic anhydrase 9 (CA...... (Source: SEC reports)

Company News:
2018-06-02 18:06:37
Dendreon Publishes New Data in Clinical Cancer Research Correlating the Magnitude of Cytotoxic T Cell Response to PROVENGE (sipuleucel-T) Treatment with Overall Survival
2018-06-02 17:31:11
Dendreon Publishes New Data in Clinical Cancer Research Correlating the Magnitude of Cytotoxic T Cell Response to PROVENGE (sipuleucel-T) Treatment with Overall Survival
2018-05-18 18:07:00
Dendreon Initiates Large-Scale Clinical Trial to Investigate PROVENGE (sipuleucel-T) in Men with Early-Stage Prostate Cancer on Active Surveillance
2018-05-18 17:31:07
Dendreon Initiates Large-Scale Clinical Trial to Investigate PROVENGE (sipuleucel-T) in Men with Early-Stage Prostate Cancer on Active Surveillance
2017-11-08 17:30:32
Dendreon Appoints Bruce A. Brown, M.D. to Lead R&D Organization
2017-11-08 17:00:57
Dendreon Appoints Bruce A. Brown, M.D. to Lead R&D Organization
2017-10-26 17:30:33
Dendreon Strengthens Executive Team with Key Management Appointments
2017-10-26 17:01:01
Dendreon Strengthens Executive Team with Key Management Appointments
2017-06-29 18:06:19
Sanpower Group Closes Acquisition of Dendreon
2017-06-29 17:12:14
Sanpower Group Closes Acquisition of Dendreon

People in the same industry: